086820.KQ Biosolution Co.Ltd

Healthcare Pharmaceuticals KOSDAQ
5,370 KRW
Close of Oct 31, 2026
5,210 13,450
Market cap
KRW 139B
P/E
162.1x
P/B
3.35x
ROE
-13.4%
Dividend yield
-
Fundamental score
1.3/5

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 086820.KQ undervalued?

Graham number

The Graham number of Biosolution Co.Ltd cannot be estimated reliably (the estimate is too far from the market price).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biosolution Co.Ltd fundamental analysis

5 of 21 checks passed

ROE 0/2

Low return on equity (-13.4%), below 10%.

ROA 0/1

Return on assets (-8.4%) is below the industry median (3.4%).

Profit Consistency 0/2

Not profitable for at least 3 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 0/1

Not enough positive earnings history to compare last year's growth with the 5-year average.

Earnings Growth vs Industry 1/1

Last year's EPS growth (102.1%) is above the industry median (6.6%).

Revenue Growth 2/2

Revenue grew 14.6% a year over the past 3 years.

Short-term Liquidity 0/1

Current assets do not cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 0/2

Debt to equity cannot be calculated: debt is not reported or equity is negative.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Cash Runway 2/2

Cash covers 10.9 years of the current cash burn.

PE vs Market 0/1

PE (162.1x) is above the market median (11.3x).

PE vs Industry 0/1

PE (162.1x) is above the industry median (19.4x).

PBV 0/1

Price to book (3.4x) is above the industry median (0.8x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 543.9, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 0/2

No dividend paid in the last reported year.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 0/1

Dividends paid did not grow over the past 5 years.

Payout Ratio 0/1

No dividend, or no profit to pay it from.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biosolution Co.Ltd stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biosolution Co.Ltd

Bio Solution Co.,Ltd. develops, manufactures, and sells cell therapy products worldwide. The company offers CartiLife, an autologous chondrocyte cell-based therapy for the restoration of symptomatic and structural complications caused by articular cartilage defects; KeraHeal-Allo, a thermosensitive hydrogel-type allogenic keratinocyte cell-therapy product to promote re-epithelialization of deep 2nd-degree burn wounds; and KeraHeal, an autologous spray-type keratinocyte cell-…

Full company profile